ArticleFrontiers in oncology2022

Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer.

Pedro C Lara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.